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ABSTRACT
Introduction: Pemphigus foliaceus is an autoimmune disease with bullous man-
ifestations on the surface of the skin that requires long-term administration of 
immunosuppressive medications. Kaposi’s sarcoma is one of the diseases that 
manifest in people with innate or acquired immune systems deficiency with the 
direct involvement of HHV-8 and causes polypoid skin lesions. Case presenta-
tion: This study was conducted on a 78-year-old man with a history of pemphigus 
foliaceus treated with immunosuppressive drugs. Conclusion: In this patient, a 
secondary polypoid lesion had been created around the anus and the results of 
pathological tests had confirmed the Kaposi’s Sarcoma.
INTRODUCTION
Pemphigus foliaceus (PF) is an autoimmune disease with 
blisters on the surface of the skin that does not manifest 
on the bullous mucosa (1,2). The prevalence of PF varies 
worldwide so that it ranges from 1-0.5 per 1 million people 
in Western Europe and 6.7 patients per 1 million people in 
Tunisia. Although it is generally recognized as a sporadic 
disease around the world, it is endemic in Brazil located in 
South America (3). 
Kaposi’s sarcoma (KS) is a benign vascular neoplasm in 
immunosuppressed individuals, especially in human immu-
nodeficiency virus (HIV)-infected individuals (4,5). Herpes-
virus 8 (HHV-8) infection is involved in the creation of this 
vascular tumor (6). This disease is common in Eastern Eu-
rope, the Mediterranean, and North Africa in men with the 
age range of 64 and 72 years. It is also known as endemic in 
the Sahara Desert of Africa (6). 
The present case study was conducted on an Iranian male 
patient with a history of PF who was treated with cortico-
steroids and rituximab. Five months after the first dose of 
corticosteroid, KS polypoid ulcerative lesion manifested. 
CASE PRESENTATION
The case of this study is a 78-year-old Iranian patient suffer-
ing PF since 2019. He had bullous lesions on the head and 
neck of the dorsal body and upper and lower limbs in the 
form of skin blisters. In addition, no lesion was observed on 
the surface mucosa, including oral mucosa. A biopsy of 0.3 
cm from the patient’s skin showed intraepidermal acanthol-
ytic blisters. In addition, in the upper dermis area, moderate 
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Figure 1. The lesion created in the anal area of the patient
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2infiltration of lymphocytic, neutrophilic, and eosinophilic 
cells was observed around the superficial blood vessels. Its 
result was confirmed diagnosis of PF. 
The patient was treated with corticosteroid prednisolone 
pulse at a dose of 1 g/day for 3 days, followed by receiving 
an intravenous infusion of rituximab at a dose of 500mg / 
50ml once per week for 4 weeks. In addition, after three days 
of receiving prednisolone pulse at the mentioned dose, he re-
ceived 60 mg daily oral prednisolone for 2 weeks, followed 
by a dose reduction for 90 days. All blisters were resolved 
after the considered treatments. Five months (20 weeks) af-
ter receiving the first dose of corticosteroid, the patient no-
ticed a lesion in the area around the anus that developed into 
an ulcerative polypoid after 1.5 months of growth (Figure 
1). He underwent lesion resection surgery and the lesion was 
sent to the pathological laboratory for examination.
The results of pathologic tests showed that the polypoid le-
sion was at dimensions of 3.5 ×  2 ×  1 cm and resected 
tumoral lesion cells were positive in terms of infection with 
herpesvirus 8 (HHV-8), CD31, and CD34. Ki-67 was also 
positive in 40-45% of tumoral cells and the tumor cells were 
morphologically consistent with KS, confirming the diagno-
sis of KS.
DISCUSSION
KS is a benign angioproliferative neoplasm that causes pol-
ypoid lesions on the skin surface in three classes: 1) Classic 
KS, 2) Endemic KS, and 3) iatrogenic KS. The classic type 
of disease is more common in older men of Eastern Europe, 
the Mediterranean, and North Africa, but its endemic type is 
more common in Sahara Desert of Africa especially in peo-
ple with the age range of 25-40 years. The incidence of KS 
is highly correlated with decreased immunity, so that as this 
disease is much more prevalent in HIV-infected people and 
transplant recipients who have lower immunogenicity than 
healthy individuals (4, 5) The iatrogenic types of KS are seen 
in patients who have used immunosuppressive drugs such as 
cyclosporine, corticosteroid, and rituximab (6). The case re-
ported in this study also had a history of taking prednisolone 
and rituximab.
Based on the reports of the researchers around the world, KS 
can manifest during the treatment of bullous pemphigoid with 
steroids and methotrexate. Therefore, it can be suggested that 
the treatment of chronic autoimmune diseases with immu-
nosuppressive drugs may increase the risk of iatrogenic KS. 
Another study (8) showed that a person was affected by KS 
with receiving short-term doses of immunosuppressive drugs, 
including steroids and methotrexate. The results confirm the 
efficacy of the medications received by the patient in the pres-
ent study in the incidence of KS.
Another case report of iatrogenic KS (9) showed that a per-
son with bullous pemphigoid treated with prednisolone and 
received clobetasol was affected with KS. This case study 
indicates the effect of immunosuppressive drugs on the inci-
dence of this disease. The present study is a rare case in which 
the patient was affected by KS after being affected by PF and 
receiving the treatments. Similar case reports are rare around 
the world. Researchers can investigate the effects of immuno-
suppressive drugs such as those used on the case. Moreover, 
such studies try to prescribe a safer dose of the drug according 
to the patient’s age and condition and reduce the incidence of 
such lesions by moderating the dose.
CONCLUSION
Finally, it can be concluded that the use of prednisolone and 
rituximab in the 78-year-old patient resulted in a lesion in 
the anus area. The cells of this polypoid lesion were posi-
tive for HHV-8 infection. The results showed that CD31 and 
CD34 were positive, confirming the iatrogenic KS.
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